Tinea corporis at the injection site of interleukin-17 inhibitor in psoriasis vulgaris
We report a patient with psoriasis vulgaris who developed tinea corporis at the injection site of ixekizumab, an IL-17 inhibitor. This case suggests that local inhibition of IL-17 may reduce dermatophyte resistance, leading to site-specific fungal infections.
Authors
- Atsushi Otsuka (ORCID: https://orcid.org/0000-0001-7365-947X)
- Keigo Takase
- Kenji Kabashima (ORCID: https://orcid.org/0000-0002-0773-0554)
- Toshiaki Kogame (ORCID: https://orcid.org/0000-0002-0683-719X)
- Takayoshi Komatsu‐Fujii (ORCID: https://orcid.org/0000-0002-3085-6956)
Institutions
- Agency for Science, Technology and Research (SG)
- Kyoto University (JP)
- Kindai University (JP)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1093/bjd/ljae511
- Primary Topic
- Nail Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00